Table 4.
Univariable and Multivariable Analysis of Factors Associated with Prevalence of Treatment
| Adjuvant Therapy Receipt (n = 164)a |
Completion of Prescribed Adjuvant Chemotherapy (n = 81)b |
|||
|---|---|---|---|---|
| Data Variable | Univariable | Multivariable | Univariable | Multivariable |
| PrRa (95% CI) | PrR (95% CI) | PrR (95% CI) | PrR (95% CI) | |
| Agea | ||||
| < 50 years | REF | REF | REF | REF |
| ≥ 50 years | 1.0 (0.7–1.5) | 1.0 (0.7–1.5) | 0.8 (0.5–1.5) | 0.9 (0.5–1.6) |
| Referralb | 0.9 (0.6–1.3) | 0.9 (0.6–1.3) | 0.9 (0.5–1.6) | 0.8 (0.5–1.6) |
| Mwanza Cityc | 1.0 (0.7–1.8) | 1.0 (0.6–1.7) | 1.0 (0.5–2.1) | 1.1 (0.6–2.1) |
| Insurance | 1.5 (1.0–2.2) | 1.3 (0.9–2.0) | 1.8 (1.0–3.2) | 1.7 (0.9–3.1) |
| Histopathological Diagnosisd | 3.0 (1.7–5.4) | 3.0 (1.7–5.4) | 1.1 (0.4–2.7) | 1.4 (0.5–3.5) |
| Clinically Positive Nodese | 1.1 (0.6–1.9) | 1.0 (0.6–1.9) | 1.6 (0.8–3.1) | 1.4 (0.7–2.9) |
| Suspected Distant Metastasesf | 1.1 (0.7–1.8) | 1.2 (0.7–2.2) | 1.8 (1.0–3.4) | 1.5 (0.7–3.3) |
aCategorized based on median age, bChart documented referral (slip or mention), cresidence in vs. out of Mwanza city, dAs documented in the chart, eDocumentation of palpable axillary lymphadenopathy with or without targeted breast imaging, fImaging suspicious for distant disease (pulmonary/abdominal/skeletal)
PrR prevalence ratio